Assessment the Effect of Human Umbilical Cord Wharton's Jelly Stem Cells on the Exprssion of Homing Genes; CXCR4 and VLA-4 in Cell Lline of Breast Cancer
Background: Breast cancer is the most common cancer in women. The prevalence of breast cancer in Western women is one in eight. Although the prevalence of breast cancer in Iran is lower than in Western countries (one in every 10-12 women), the incidence of breast cancer in it is 5-10 years earlier than in Western countries. Breast cancer is the second leading cause of cancer death among women after lung cancer. Therefore, finding new therapeutic methods could potentially help to reduce breast cancer mortality and increase the survival rate. Wharton jelly stem cells with mesenchymal morphology play an important role in inhibiting the progression of ovarian, osteosarcoma, and breast cancer by inducing apoptoses and reducing metastasis. Several environmental and genetic factors are involved in the occurrence of breast cancer. CXCR4 and VLA-4 genes are important genetic factors in breast cancer that play a role in cell survival, migration, proliferation and metastasis of several types of cancer, especially breast cancer. Therefore, inhibition of these two genes by Wharton's Jelly Stem Cells could be a novel and effective therapeutic target in breast cancer. The aim of this study was to investigate the effect of Wharton jelly stem cells secretion on the expression of CXCR4 and VLA-4 genes in cancer cells.
Materials and Methods: These cells were exposed to Wharton's Jelly Stem Cells after culturing breast cancer cells. RNA was extracted from treated cells. The expression of CXCR4 and VLA-4 genes was evaluated by real-time PCR.
Results: The results of the MTT and Scratching tests showed a significant difference compared to the control group. Also, the results of Real-time PCR showed a significant decrease in the expression of CXCR4 and VLA-4 genes compared to the control group.
Conclusion: The results of this study showed that different concentrations of Wharton Jelly Stem Cells Reduce Cancer Cell Growth and Expression of CXCR-4 and VLA-4 Homing Genes in Breast Cancer Cell Line. Therefore, it can be considered that Wharton Jelly Stem Cells can be suggested as an effective treatment for breast cancer.
2. Kobayashi K, Kubota T, Aso T. Study on myofibroblast differentiation in the stromal cells of Wharton's jelly: expression and localization of α-smooth muscle actin. Early Hum Dev. 1998 51(3):223-33.
3. De Miguel MP, Montiel FA, Iglesias PL, et al. Epiblast-derived stem cells in embryonic and adult tissues. Int J Dev Biol. 2009;53(8-10):1529-40.
4. Pappa KL, Anagnou NP. Novel sources of fetal stem cells: where do they fit on the developmental continuum?. Regen Med . 2009;4(3):423-33.
5. Carlin R, Davis D, Weiss M, et al. Expression of early transcription factors Oct-4, Sox-2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reprod Biol Endocrinol . 2006;4:8.
6. La Rocca G, Anzalone R, Corrao, Francesca S, et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol. 2009;131(2):267-82.
7. Hendijani F, Javanmard SH. Dual protective and cytotoxic benefits of mesenchymal stem cell therapy in combination with chemotherapy/radiotherapy for cancer patients. Crit Rev Eukaryot Gene Expr. 2015;25(3):203-7.
8. Ahn JO, Coh YR, Lee HW, et al. Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo. Anticancer Res. 2015;35(1):159-68.
9. Ganta C , Chiyo D, Ayuzawa R, et al. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post–tumor cell inoculation. Cancer Res. 2009;69(5):1815-20.
10. Rachakatla RS, Marini F, Weiss ML, et al. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther. 2007;14(10):828-35.
11. Gauthaman k , Fong CY, Suganya CA, et al. Extra-embryonic human Wharton’s jelly stem cells do not induce tumorigenesis, unlike human embryonic stem cells. Reprod Biomed Online. 2012;24(2):235-46.
12. Khakoo Ak, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 2006;203(5):1235-47.
13. Ayuzawa R, Doi C, Rachakatla RS, et al. Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett . 2009;280(1):31-7.
14. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
15. Vaidya VS, Welch DR. Metastasis suppressors and their roles in breast carcinoma. J Mammary Gland Biol Neoplasia . 2007;12(2-3):175-90.
16. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta. 2009;1796(2):293-308.
17. Mitchell KE , Weiss ML, Mitchell BM, et al. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells. 2003;21(1):50-60.
18. Yoon HH, Jung BY, Seo YK, et al. In vitro hepatic differentiation of umbilical cord-derived mesenchymal stem cell. Process Biochemistry, vol. 45, no. 12, pp. 1857-1864, 2010.
19. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742-57.
20. Semenov OV, Breymann C. Mesenchymal stem cells derived from Wharton's jelly and their potential for cardio-vascular tissue engineering. Tissue Eng Regen Med.2011;4:64-71.
21. Zola H , Swart B, Banham A, et al. CD molecules 2006—human cell differentiation molecules. J Immunol Methods. 2007;319(1-2):1-5.
22. Knoblich JA. Mechanisms of asymmetric stem cell division. Cell. 2008;132(4):583-97.
23. Frank SA, Iwasa Y, Nowak MA. Patterns of cell division and the risk of cancer. Genetics. 2003;163(4):1527-32.
24. Gauthaman K, Yee FC, Cheyyatraivendran S, et al. Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. J Cell Biochem. 2012;113(6):2027-39.
25. Secchiero P , Zorzet S, Tripodo C, et al. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One. 2010;5(6):e11140.
26. Reuter S, Eifes S, Dicato M, et al. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol. 2008;76(11):1340-51.
27. Hideshima T, Chauhan D, Hayashi T, et al. The Biological Sequelae of Stromal Cell-derived Factor-1α in Multiple Myeloma. Mol Cancer Ther. 2002;1(7):539-44.
28. Libura J, Drukala J, Majka M, et al. CXCR4–SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood. 2002;100(7):2597-606.
29. Xu C, Zhao H, Chen H, et al. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953-64.
30. Kim JH, Lee HJ, Song YS. Stem cell based gene therapy in prostate cancer. Biomed Res Int. 2014;2014:549136.
31. Zhang C, Yang SJ , Wen Q, et al. Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. J Cancer. 2017;8(1):85-96.
32. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14(3):171-9.
33. Abe M, Hiura K, Ozaki S, et al. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4–VCAM-1 adhesion and macrophage inflammatory protein-1α and MIP-1β production. J Bone Miner Metab. 2009;27(1):16-23.
34. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev. 1992;11(3-4):353-75.
35. Albelda S. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest. 1993;68(1):
|Issue||Vol 16, No 2 (2022)|
|Wharton jelly; CXCR4; VLA-4 genes; Breast cancer|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|